Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07688070 · ClinicalTrials.gov registry record · Phase 2
Verapamil Effect in Cystic Fibrosis-related Dysglycemia
A Phase 2 study, sponsored by Rhode Island Hospital.
- Not yet
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT07688070 is a Phase 2 study that has not yet begun recruiting, run by Rhode Island Hospital. The registered enrollment target is 30 participants.
The verdict
NCT07688070, a Phase 2 study, has not yet begun recruiting, sponsored by Rhode Island Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The investigators are conducting a pilot open-label pre/post interventional trial in adolescents and adults with cystic fibrosis (CF) and abnormal glucose tolerance or early CF-related diabetes mellitus (CFRD) to assess the safety and efficacy of verapamil on beta cell function and dysglycemia.
Interventions
- DRUG Verapamil Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2028-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07688070
The ClinicalTrials.gov registry entry for NCT07688070 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rhode Island Hospital, which has 130 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Verapamil Hydrochloride is the first listed.
NCT07688070 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07688070 about?
NCT07688070 is a clinical study titled "Verapamil Effect in Cystic Fibrosis-related Dysglycemia". The investigators are conducting a pilot open-label pre/post interventional trial in adolescents and adults with cystic fibrosis (CF) and abnormal glucose tolerance or early CF-related diabetes mellitus (CFRD) to assess the safety and efficacy of verapamil on beta cell function and dysglycemia.
What is the current status of trial NCT07688070?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-08-01. Estimated completion is 2028-08-31.
What interventions are being tested in trial NCT07688070?
The interventions under investigation include: Verapamil Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT07688070?
This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.